The clinical diagnosis of AD currently relies on neurophysiological examination and neuroimaging, such as mini-mental state examination (MMSE), activities of daily living (ADL), Montreal Cognitive Assessment test (MoCA), and physiological examination of cerebrospinal fluid (CSF β 1-42, T-tau, P-tau), mainly leading to complementary explorations, such as single-photon emission computed tomography (SPECT) or positron emission tomography (PET; Mattsson et al., 2015, 2018;Roalf et al., 2017;Li et al., 2018;Meyer et al., 2020). The gene discussed is MAPT; the disease is Alzheimer disease.